• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears AI-Powered Brain Volumetry Software for MRI


The artificial intelligence (AI)-enabled AIRAscore can reportedly provide quantitative brain volume data within five minutes of assessing brain MRI scans.

The Food and Drug Administration (FDA) has granted 510(k) clearance for AIRAscore, an artificial intelligence (AI)-powered software that may facilitate earlier detection of Alzheimer’s disease and other forms of dementia through quantitative brain volume analysis based on magnetic resonance imaging (MRI) scans.

AIRAMed, the developer of the AIRAscore, said the software provides detailed assessment of lobes and limbic structures in the brain to help detect patterns of neurodegenerative disease and brain volumes that are not age appropriate. The company added that other benefits of the software include auto-segmentation of white matter, cerebrospinal fluid, grey matter and T1 hypointensities.

The AIRAscore findings can be beneficial in detecting and differentiating between Alzheimer’s disease, frontotemporal dementia, and other diseases with patterns of brain volume loss, according to AIRAMed.

“For so long, we’ve been limited to reading a patient’s MRI to detect Alzheimer’s and other dementias. However, we know from several studies that patients with these brain diseases suffer from subtle brain volume loss early in their disease course that cannot be observed with the human eye,” noted Tobias Lindig, M.D., the founder and managing director of AIRAMed. “With AIRAscore, we are now offering physicians a highly precise, quantitative tool for the rapid detection of areas with a brain volume below the normal range.”

Recent Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.